|Articles|September 1, 2014

Vision at all distances

The standard of care is implantation with an IOL, and with the introduction of a new lens to the European market, Dr Hamid and colleagues conducted a small trial to analyse the differences between this new option and other available lenses. Here, he presents his findings.

The standard of care with cataracts has been to remove a patient's clouded lens and provide a new monofocal intraocular lens (IOL). These monofocal lenses are excellent at providing good vision at a single, fixed focal length usually distance. However, patients must still rely on glasses for near and intermediate vision.

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Vision at all distances

Related Content

Visual training may ease neuroadaptation to presbyopia-correcting IOLs

Single-use instruments in cataract surgery: Beyond the backup role

Synthetic corneal implant shows promise in eyes with chronic corneal oedema

Hands-on training, real surgeon input: inside BVI's new Experience Hub

How the ocular microbiome may shape outcomes in keratoplasty

Latest CME

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

Treatment Optimization in the Evolving Anti-VEGF Era

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(COPE Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(COPE Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

(COPE Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

OCT-980 receives FDA orphan drug designation for retinitis pigmentosa

First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery